Rakesh serves on Prescient’s Board as a Non-Executive Director. After earning a degree in Veterinary Medicine, he completed his MS in Immunology and his PhD in Immunology and Oncology at Imperial College School of Medicine in London. He was then recruited by the oncology biotechnology firm Antisoma, which specializes in the development of antibody-based therapeutics for oncology. After working in oncology drug development for more than a decade, Rakesh joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.
Featured
Connecting Insights to Strategy
Read the article to discover leadership perspectives on how connected customer intelligence, strategic expertise and AI support better brand decisions.
News and insights
Featured
Strategy That Learns: Rethinking Brand Planning for a Changing Environment
Read the article to discover leadership perspectives on how connected customer intelligence, strategic expertise and AI support better brand decisions.
From Data-Rich to Decision-Ready
Discover why earlier, faster integration of integrated insights are a strategic imperative and now matter more than ever.
ONWARD: Driving Equitable Access and System Readiness in Cancer Care
This Dolon Institute paper highlights six interconnected barriers affecting timely access to oncology innovation, drawing on examples from healthcare systems around the world.
Careers
Work with us
If you're looking to stretch your thinking, lead with purpose, and be part of a culture that values curiosity, accountability and trust, you're in the right place.
